TRPV4 ANTAGONISTS

A combination comprising a compound of Formula (I): or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotension II receptor antagonists, va...

Full description

Saved in:
Bibliographic Details
Main Authors HAMMOND Marlys, PATTERSON Jaclyn R, STOY Patrick, CHEUNG Mui, GOODMAN Krista B, HOANG Tram H, EIDAM Hilary Schenck, HILFIKER Mark A, BROOKS Carl, YE Guosen
Format Patent
LanguageEnglish
Slovenian
Published 30.06.2016
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

Abstract A combination comprising a compound of Formula (I): or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotension II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal anti-inflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective ²-adrenoceptor and ± 1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors.
AbstractList A combination comprising a compound of Formula (I): or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotension II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal anti-inflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective ²-adrenoceptor and ± 1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors.
Author HOANG Tram H
EIDAM Hilary Schenck
CHEUNG Mui
STOY Patrick
HAMMOND Marlys
HILFIKER Mark A
PATTERSON Jaclyn R
GOODMAN Krista B
BROOKS Carl
YE Guosen
Author_xml – fullname: HAMMOND Marlys
– fullname: PATTERSON Jaclyn R
– fullname: STOY Patrick
– fullname: CHEUNG Mui
– fullname: GOODMAN Krista B
– fullname: HOANG Tram H
– fullname: EIDAM Hilary Schenck
– fullname: HILFIKER Mark A
– fullname: BROOKS Carl
– fullname: YE Guosen
BookMark eNrjYmDJy89L5WQQDAkKCDNRcPQLcXT39_MMDgnmYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxwZ5G5kaGBoZmISGGxsSoAQD1jSAN
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate ANTAGONISTI TRPV4
ExternalDocumentID SI2721016TT1
GroupedDBID EVB
ID FETCH-epo_espacenet_SI2721016TT13
IEDL.DBID EVB
IngestDate Fri Jul 19 15:54:49 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
Slovenian
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_SI2721016TT13
Notes Application Number: SI20120030564
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160630&DB=EPODOC&CC=SI&NR=2721016T1
ParticipantIDs epo_espacenet_SI2721016TT1
PublicationCentury 2000
PublicationDate 20160630
PublicationDateYYYYMMDD 2016-06-30
PublicationDate_xml – month: 06
  year: 2016
  text: 20160630
  day: 30
PublicationDecade 2010
PublicationYear 2016
RelatedCompanies Glaxosmithkline Intellectual Property (No. 2) Limited
RelatedCompanies_xml – name: Glaxosmithkline Intellectual Property (No. 2) Limited
Score 3.0400095
Snippet A combination comprising a compound of Formula (I): or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Title TRPV4 ANTAGONISTS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160630&DB=EPODOC&locale=&CC=SI&NR=2721016T1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMTJLsTRNMk7RTTM2NNY1STFL1LVIS0wGZvdkA5MU0Ing4MEcXz8zj1ATrwjTCCaGTNheGPA5oeXgwxGBOSoZmN9LwOV1AWIQywW8trJYPykTKJRv7xZi66IG7R0bmoGOkFJzcbJ1DfB38XdWc3a2DfZU8wuyNQL2dIDSIcCOEiuwFW0OygyuYU6gTSkFyDWKmyADWwDQsLwSIQam4hxhBk5n2MVrwgwcvtD5biATmvWKRRgEQ4ICwkwUHP1CHN39_TyDQ4JFGRTdXEOcPXSBZsfD_REf7AlzRYihsRgDC7B_nyrBoAA6AisR2GxKNEm0NDFPNU-yBJ0ZZmCRlpJkmJRsaCjJIIXbHCl8ktIMXKAwgSxvk2FgKSkqTZUF1qElSXJg3wMAphdymA
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMTJLsTRNMk7RTTM2NNY1STFL1LVIS0wGZvdkA5MU0Ing4MEcXz8zj1ATrwjTCCaGTNheGPA5oeXgwxGBOSoZmN9LwOV1AWIQywW8trJYPykTKJRv7xZi66IG7R0bmoGOkFJzcbJ1DfB38XdWc3a2DfZU8wuyNQL2dIDSIcCOEiuwhW0OygyuYU6gTSkFyDWKmyADWwDQsLwSIQam4hxhBk5n2MVrwgwcvtD5biATmvWKRRgEQ4ICwkwUHP1CHN39_TyDQ4JFGRTdXEOcPXSBZsfD_REf7AlzRYihsRgDC7B_nyrBoAA6AisR2GxKNEm0NDFPNU-yBJ0ZZmCRlpJkmJRsaCjJIIXbHCl8kvIMnB4hvj7xPp5-3tIMXKDwgSx1k2FgKSkqTZUF1qclSXLgkAAAL_V1iw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=TRPV4+ANTAGONISTS&rft.inventor=HAMMOND+Marlys&rft.inventor=PATTERSON+Jaclyn+R&rft.inventor=STOY+Patrick&rft.inventor=CHEUNG+Mui&rft.inventor=GOODMAN+Krista+B&rft.inventor=HOANG+Tram+H&rft.inventor=EIDAM+Hilary+Schenck&rft.inventor=HILFIKER+Mark+A&rft.inventor=BROOKS+Carl&rft.inventor=YE+Guosen&rft.date=2016-06-30&rft.externalDBID=T1&rft.externalDocID=SI2721016TT1